Rossari Biotech Q4 FY26 Revenue Hits Record Rs 684.9 Crore

Rossari Biotech reported record Q4 FY26 revenue of Rs 684.9 crore, up 18% YoY, with full-year revenue at Rs 2,396.4 crore growing 15%.
Management announced a strategic review to divest non-core B2C businesses and rephased a Rs 192 crore CAPEX plan to Rs 50-75 crore for FY27.
The company plans to reduce debt significantly over 18 months through operational cash flows and the sale of non-core assets, including an office space sale generating Rs 19 crore.
Key growth drivers for FY27 include new ethoxylation capacity, expansion into pharma and aroma chemicals, and the new Thailand blending facility targeting Rs 50-75 crore peak revenue.